Patient characteristics and treatment requirement according to age at TRA start and use of eltrombopag or romiplostim as first TRA
| Patient characteristics . | All patients (N = 384) . | Age 60-74 y (n=226) . | Age ≥ 75 y (n = 158) . | P . | Eltrombopag (n = 271) . | Romiplostim (n = 113) . | P . |
|---|---|---|---|---|---|---|---|
| Males | 185 (48.2) | 96 (42.5) | 89 (56.3) | .01 | 137 (50.5) | 48 (42.5) | .15 |
| Platelet count at ITP diagnosis, median (range) | 18 (1-90) | 16 (1-90) | 20 (1-87) | .23 | 20 (1-90) | 15 (1-90) | .05 |
| Hemoglobin at diagnosis, median (range), g/dL | 13.4 (5.4-17.4) | 13.5 (6.5-17.4) | 13.4 (5.4-17.1) | .36 | 13.4 (5.9-17.4) | 13.5 (5.4-16.8) | .35 |
| Leukocyte count (×109/L) at ITP diagnosis, median (range) | 6.8 (2.9-18.8) | 7.0 (2.9-18.8) | 6.6 (3.1-14.5) | .29 | 6.8 (2.9-18.8) | 6.8 (3.1-12.2) | .88 |
| CCI value, median (range) | 1 (0-10) | 1 (0-10) | 1.5 (0-10) | <.001 | 1 (0-10) | 1 (0-8) | .12 |
| CCI ≥1 | 226 (58.9) | 117 (51.8) | 109 (69.0) | .001 | 157 (57.9) | 69 (61.1) | .57 |
| Patients with ≥1 CVRF Diabetes Hypertension Overweight Dyslipidemia Smoking | 317 (82.6) 108 (28.1) 225 (58.6) 121 (53.5) 70 (18.2) 31 (8.1) | 176 (77.9) 60 (26.6) 116 (51.3) 121 (53.5) 41 (18.1) 23 (10.2) | 141 (89.2) 48 (30.4) 109 (69.0) 79 (50.0) 29 (18.4) 8 (5.1) | .004 .41 .001 .49 .96 .07 | 230 (84.9) 72 (26.6) 160 (59.0) 147 (54.2) 49 (18.1) 25 (9.2) | 87 (77.0) 36 (31.9) 65 (57.5) 53 (46.9) 21 (18.6) 6 (5.3) | .06 .29 .78 .19 .91 .20 |
| Time from ITP diagnosis to first TRA start, median (range), y | 2.0 (0-57) | 2.4 (0-57) | 1.2 (0-40.2) | <.001 | 1.9 (0-40.3) | 2.4 (0-57) | .36 |
| Age at first TRA start, median (range), y | 73 (60-94.4) | 67.5 (60-74.9) | 79.3 (75-94.4) | <.001 | 73.4 (60-94.4) | 72.0 (60-92.8) | .03 |
| Anticoagulant therapy at first TRA start | 26 (6.8) | 10 (4.4) | 16 (10.1) | .03 | 23 (8.5) | 3 (2.7) | .04 |
| Antiplatelet therapy at first TRA start | 29 (7.6) | 16 (7.1) | 13 (8.2) | .68 | 21 (7.8) | 8 (7.1) | .82 |
| Thrombosis any grade before first TRA start | 82 (21.4) | 37 (16.4) | 45 (28.5) | .004 | 61 (22.5) | 21 (18.6) | .39 |
| Hemorrhage any grade before first TRA start | 185 (48.2) | 108 (47.8) | 77 (48.7) | .86 | 129 (47.6) | 56 (49.6) | .73 |
| TRA start in chronic phase | 236 (61.5) | 154 (68.1) | 82 (51.9) | .001 | 166 (61.3) | 70 (61.9) | .90 |
| TRA start as at least third-line treatment | 226 (58.9) | 148 (65.5) | 78 (49.4) | .002 | 158 (58.3) | 68 (60.2) | .73 |
| Patient characteristics . | All patients (N = 384) . | Age 60-74 y (n=226) . | Age ≥ 75 y (n = 158) . | P . | Eltrombopag (n = 271) . | Romiplostim (n = 113) . | P . |
|---|---|---|---|---|---|---|---|
| Males | 185 (48.2) | 96 (42.5) | 89 (56.3) | .01 | 137 (50.5) | 48 (42.5) | .15 |
| Platelet count at ITP diagnosis, median (range) | 18 (1-90) | 16 (1-90) | 20 (1-87) | .23 | 20 (1-90) | 15 (1-90) | .05 |
| Hemoglobin at diagnosis, median (range), g/dL | 13.4 (5.4-17.4) | 13.5 (6.5-17.4) | 13.4 (5.4-17.1) | .36 | 13.4 (5.9-17.4) | 13.5 (5.4-16.8) | .35 |
| Leukocyte count (×109/L) at ITP diagnosis, median (range) | 6.8 (2.9-18.8) | 7.0 (2.9-18.8) | 6.6 (3.1-14.5) | .29 | 6.8 (2.9-18.8) | 6.8 (3.1-12.2) | .88 |
| CCI value, median (range) | 1 (0-10) | 1 (0-10) | 1.5 (0-10) | <.001 | 1 (0-10) | 1 (0-8) | .12 |
| CCI ≥1 | 226 (58.9) | 117 (51.8) | 109 (69.0) | .001 | 157 (57.9) | 69 (61.1) | .57 |
| Patients with ≥1 CVRF Diabetes Hypertension Overweight Dyslipidemia Smoking | 317 (82.6) 108 (28.1) 225 (58.6) 121 (53.5) 70 (18.2) 31 (8.1) | 176 (77.9) 60 (26.6) 116 (51.3) 121 (53.5) 41 (18.1) 23 (10.2) | 141 (89.2) 48 (30.4) 109 (69.0) 79 (50.0) 29 (18.4) 8 (5.1) | .004 .41 .001 .49 .96 .07 | 230 (84.9) 72 (26.6) 160 (59.0) 147 (54.2) 49 (18.1) 25 (9.2) | 87 (77.0) 36 (31.9) 65 (57.5) 53 (46.9) 21 (18.6) 6 (5.3) | .06 .29 .78 .19 .91 .20 |
| Time from ITP diagnosis to first TRA start, median (range), y | 2.0 (0-57) | 2.4 (0-57) | 1.2 (0-40.2) | <.001 | 1.9 (0-40.3) | 2.4 (0-57) | .36 |
| Age at first TRA start, median (range), y | 73 (60-94.4) | 67.5 (60-74.9) | 79.3 (75-94.4) | <.001 | 73.4 (60-94.4) | 72.0 (60-92.8) | .03 |
| Anticoagulant therapy at first TRA start | 26 (6.8) | 10 (4.4) | 16 (10.1) | .03 | 23 (8.5) | 3 (2.7) | .04 |
| Antiplatelet therapy at first TRA start | 29 (7.6) | 16 (7.1) | 13 (8.2) | .68 | 21 (7.8) | 8 (7.1) | .82 |
| Thrombosis any grade before first TRA start | 82 (21.4) | 37 (16.4) | 45 (28.5) | .004 | 61 (22.5) | 21 (18.6) | .39 |
| Hemorrhage any grade before first TRA start | 185 (48.2) | 108 (47.8) | 77 (48.7) | .86 | 129 (47.6) | 56 (49.6) | .73 |
| TRA start in chronic phase | 236 (61.5) | 154 (68.1) | 82 (51.9) | .001 | 166 (61.3) | 70 (61.9) | .90 |
| TRA start as at least third-line treatment | 226 (58.9) | 148 (65.5) | 78 (49.4) | .002 | 158 (58.3) | 68 (60.2) | .73 |
Unless otherwise noted, data are n (%). Values of P < .05 indicate significant associations, are in bold. Previous thromboses include acute myocardial infarction, transient ischemic attack/stroke, superficial/deep vein thrombosis, and acute/chronic arterial obstructive disease.